Molecular-Based Haplotype Analysis of the β 2-Adrenergic Receptor Gene (ADRB2) in Japanese Asthmatic and Non-Asthmatic Subjects  by Munakata, Mitsuru et al.
Molecular-Based Haplotype Analysis
of the2-Adrenergic Receptor Gene
(ADRB2) in Japanese Asthmatic and
Non-Asthmatic Subjects
Mitsuru Munakata1, Yosuke Harada2, Takashi Ishida1, Junpei Saito1, Akira Nagabukuro2, Hiro-
shi Matsushita3, Nobuyuki Koga3, Masaaki Ohsaki3, Kenichi Imagawa3 and Takayuki Shiratsuchi2
ABSTRACT
Background: The β2-adrenergic receptor gene (ADRB2) is a target molecule of β2-agonists. Single nucleo-
tide polymorphisms (SNPs) in the ADRB2 are related to the effectiveness of β2-agonists. However, there are
some discrepancies in the results of pharmacogenetic studies of ADRB2 among different ethnic groups. The
aims of this study were to determine the ADRB2 haplotypes and diplotypes in Japanese asthmatic and non-
asthmatic subjects and to examine their relation to asthma and to compare these results with previous studies
done in other ethnic groups.
Methods: Complete sequences for 3 kb promoter and 1.2 kb structural regions of ADRB2 were analyzed in 48
Japanese asthmatics and 100 controls, and haplotypes and diplotypes of SNPs were analyzed.
Results: Fifteen SNPs including a novel one in −839 were observed. Allele frequencies for all SNPs were
similar between asthmatics and controls. We also identified 42 haplotypes and 54 diplotypes of ADRB2 in a
Japanese population. The frequencies were similar between the two groups. They were classified into 17 and
23 types, respectively, according to Drysdale’s haplotype-organization system, and a significant ethnic differ-
ence was observed between the Japanese and Caucasian populations.
Conclusions: The frequencies of SNPs and ADBR2 haplotypes in Japanese are different from those in Cau-
casians and African Americans. These divergences might imply the need for independent pharmacogenetic
studies for ADBR2 in each ethnic group.
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INTRODUCTION
With the completion of the Human Genome Project,
the role of genomic variations in disease acquisition
has become easier to define. Recently, single nucleo-
tide polymorphisms (SNPs) have been favored as
more tractable genotypic markers , and have been
utilized extensively in human genetic studies ranging
from comparative population variation to pharmaco-
genomics. Such SNPs have been reported to modu-
late pharmacodynamic reactions in individuals on ex-
posure to drugs.1-3 More recently, the grouping and
interaction of several SNPs in haplotypes has been
recognized as more important than individual SNPs
for pharmacogenomic studies. The identified haplo-
types for the mu opioid receptor gene (OPRM1) were
associated with heroin and cocaine dependence.4 In
another study, the interaction of multiple SNPs within
a haplotype of the β 2-adrenergic receptor gene
(ADRB2) was reported to correlate with individual re-
sponses to β2-stimulants, whereas no correlation was
found with individual SNPs.5
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ADRB 2 is an intronless gene on chromosome
5q31q32 that encodes 413 amino acids. It has been
implicated as a candidate gene responsible for
asthma susceptibility.6,7 Nine SNPs in the coding re-
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p value
FrequencyNumber of genotype
GenotypeAleleLocation
SNP posi-
tion nu-
cleotide Non-asthmaAsthma
Non-asthma 
(n＝100)
Asthma 
(n＝46)
0.2110.575/0.4250.652/0.34836 : 43 : 2120 : 20 : 06TT : TA : AAT/A5’－1,429
0.7660.840/0.1600.826/0.17471 : 26 : 332 : 12 : 2GG : GA : AAG/A5’－1,343
0.9480.840/0.1600.837/0.16371 : 26 : 333 : 11 : 2GG : GA : AAG/A5’－1,023
0.4400.965/0.0350.946/0.05493 : 7 : 041 : 5 : 0TT : TG : GGT/G5’－839
－1.000/0.0001.000/0.000100 : 0 : 046 : 0 : 0CC : CA : AAC/A5’－709
0.2740.590/0.4100.522/0.47838 : 42 : 2012 : 24 : 10GG : GA : AAG/A5’－654
0.7250.925/0.0750.913/0.08785 : 15 : 039 : 6 : 1CC : CG : GGC/G5’－468
－1.000/0.0001.000/0.000100 : 0 : 046 : 0 : 0CC : CT : TTC/T5’－406
0.7250.925/0.0750.913/0.08785 : 15 : 039 : 6 : 1TT : TC : CCT/C5’－367
0.9730.890/0.1100.891/0.10978 : 22 : 037 : 8 : 1TT : TC : CCT/CBUP Cys/Arg－47
0.9730.890/0.1100.891/0.10978 : 22 : 037 : 8 : 1TT : TC : CCT/C5’－20
0.2820.535/0.4650.467/0.53330 : 47 : 2311 : 21 : 14GG : GA : AAG/Aaa16 Gly/Arg46
0.6100.930/0.0700.913/0.08786 : 14 : 039 : 6 : 1CC : CG : GGC/Gaa27 Gln/Glu79
－1.000/0.0001.000/0.000100 : 0 : 046 : 0 : 0GG : GA : AAG/Aaa34 Val/Met100
0.1770.580/0.4200.663/0.33737 : 42 : 2121 : 19 : 6GG : GA : AAG/Asyn252
－1.000/0.0001.000/0.000100 : 0 : 046 : 0 : 0CC : CT : TTC/Taa164 Thr/Ile491
0.2420.580/0.4200.652/0.34837 : 42 : 2121 : 18 : 7CC : CA : AAC/Asyn523
0.5690.525/0.4750.489/0.51131 : 43 : 2612 : 21 : 13CC : CG : GGC/Gsyn1053
－1.000/0.0001.000/0.000100 : 0 : 046 : 0 : 0TT : TA : AAT/Aaa366 Tyr/End1098
0.8130.605/0.3950.620/0.38042 : 37 : 2118 : 21 : 07AA : AG : GGA/Gsyn1239
 Abbreviations: 5’ ,5’ upstream of ADRB2 ORF; aa, amino acid; BUP, ADRB2 upstream peptide; syn, synonymous.
Table 2 Localization of SNPs, identification of alele frequencies and genotypes in ADRB2
gion and 10 in the 5 ’ promoter region have so far
been reported to be associated with asthma severity. 8,9
No evidence of linkage to qualitative measures of
asthma and other respiratory diseases was seen at
the SNPs of codon 16 or 27,10-12 although there have
been no previous reports of haplotype relevance to
asthma etiology. We previously performed a prospec-
tive study with Japanese asthmatic subjects and re-
ported that the Gly16Gly16 genotype is related to
the adverse responses during β2-agonist regular-use
in Japanese asthmatics.13 On the contrary, a recent
relatively large prospective study has suggested that
adverse effects of regular inhalational therapy with β
2-agonist occur in Caucasian asthmatic subjects with
the Arg16Arg16 genotype.14
The ultimate value of SNPs for linkage and
association-mapping studies depends, in part, on the
distribution of SNP allele frequencies and inter-
marker linkage disequilibrium (LD) across popula-
tions.15 In the field of drug metabolism, many SNPs
have been identified that differ in frequency among
different ethnic groups. 16 Numerous studies have in-
dicated that the distribution of haplotype frequencies
and LD might vary substantially among different
populations. 15-17 It is therefore apparent that further
evaluation of the role of ADRB2 haplotypes in asthma
pathogenesis and drug response requires the investi-
gation of haplotypes in each ethnic group.
The aims of the present study were as follows: first,
to identify novel SNPs ; second , to determine the
ADRB2 haplotypes and diplotypes in Japanese asth-
matic and non-asthmatic subjects using molecular-
based techniques; and third, to determine whether
these haplotypes and diplotypes contribute to individ-
ual differences in susceptibility to asthma. We also
compared the frequencies of the ADRB2 haplotypes
and diplotypes between Japanese and other ethnic
groups to evaluate the differences in distribution of
ADRB2 SNPs.
METHODS
SUBJECTS
Forty-eight subjects with bronchial asthma were re-
cruited from the pulmonary clinic at the Fukushima
Medical University hospital, according to the follow-
ing criteria. First, the presence of at least two of the
following symptoms: recurrent cough, wheezing or
dyspnea. Second, increased airway responsiveness to
methacholine or the presence of reversible airflow
limitation; the latter refers to 15% variability in the
forced expiratory volume during 1 s (FEV1), or in the
peak expiratory flow rate with or without an inhaled
short-acting β2-agonist. The third criterion was the
absence of any other pulmonary disease.
Haplotype Analysis of ADRB2 in Japanese
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Freq-
uencyn
123910535232527946－20－47－367－468－654－839－1023－1343－1429Nucleotide:
Identifier
G/AG/CC/AG/AC/GG/AT/CT/CT/CC/GG/AT/GG/AG/AA/TAleles:
Haplotype 
(13 SNPs)
Haplotype 
(15 SNPs)
0.3 1GGCGCATTTCATGGA 4 1
0.7 2A・AA・G・・・・G・・・T 6 2
29.887ACAA・G・・・・G・・・・ 6 3
21.964・・・・・・・・・・・・・・T 4 4
7.923・・・・GGCCCGG・AAT 2 5
9.227AC・・・・・・・・・・・・T 4 6
1.0 3AC・A・G・・・・G・・・・10 7
0.3 1・・・・・G・・・・・・・・・ 5 8
0.3 1ACAA・・・・・・G・・・T16 9
0.7 2・・AA・G・・・・G・・・・ 610
3.1 9ACAA・G・・・・GG・・・ 611
0.3 1・C・A・G・・・・G・・・T1012
0.3 1A・A・・・・・・・・・・・・1813
0.3 1・・・・・・・・・・・G・・・ 414
0.3 1ACAA・・・・・・・・・・T 815
0.3 1・・・・・G・・・・G・・・・1116
5.516A・・・・・・・・・G・AAT 117
0.3 1ACA・・G・・・・・・・・T2018
1.0 3ACA・・・・・・・・・・・T1819
0.3 1AC・・・・・・・・G・・・・1920
0.7 2AC・・・・・・・・・・・・・ 421
1.4 4・・・・・・・・・・G・AAT 122
1.0 3AC・・・・・・・・G・AAT 123
0.3 1・・AA・G・・・・GG・・・ 624
0.3 1A・AA・G・・・・G・・・T 625
0.3 1・・AA・G・・・・・・・・T1526
0.3 1・CAA・G・・・・G・・・・ 627
3.1 9A・・・・・・・・・・・・・T 428
0.3 1・・AA・G・・・・G・・・T 629
0.7 2AC・・・・・・・・G・・・T1930
0.3 1A・・・・G・・・・・・・・・ 531
0.3 1A・・・・G・・・・G・・・・1132
3.1 9・・・・・GCC・・・・・・T1333
0.3 1A・・・・・・・・・G・・AT1934
0.3 1AC・・・G・・・・G・AAT1435
0.3 1・C・・・・・・・・・・・・T 436
0.3 1ACAA・・・・・・G・・・・1637
0.3 1ACA・・・・・・・GG・・・1738
0.3 1・・・A・G・・・・・・・・T2139
0.7 2ACAA・G・・・・・・・・・1540
0.3 1・・・・・・・・・・G・・・T1941
0.3 1A・・・・・・・・・G・・・T1942
Nucleotide numbering from ＋1 at the first nucleotide of the start codon. Alele: the two nucleotide possibilities at each SNP position. The 
13 SNPs refer to those used by Drysdale et al. (2000) for ADRB2 haplotype organization. SNPs not found in Japanese subjects in this 
study are omited from the table. Dot shows a base (no change) the same as that of Haplotype 1. The SNPs position of a red character 
shows the SNPs which were analyzed by Drysdale and associates.
Table 3 Localization of SNPs and identification of ADRB2 haplotypes
Non-asthmatic blood samples were collected from
100 healthy Japanese subjects with no symptoms or
history of allergic diseases . All of the participants
gave informed consent. The ethical committees of the
Fukushima Medical University , Japan, and the Ot-
suka Pharmaceutical Co., Ltd., Japan, approved this
study.
Genomic DNA was extracted from the peripheral
whole-blood leukocytes using the PUREGENETM
Blood Kit (Gentra Systems Inc., Minneapolis, MN,
USA).
Munakata M et al.
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Asians＊Hispanics/ Latinos＊African-Americans＊Caucasians＊JapaneseHaplotype＊
12.510.025.00.77.9(1)
10.026.76.348.37.9(2)
0.00.00.00.70.0(3)
45.040.029.733.036.0(4)
0.00.00.01.40.7(5)
30.013.331.313.235.6(6)
0.03.31.61.00.0(7)
0.00.00.00.70.3(8)
0.00.04.70.00.0(9)
0.03.30.00.71.4(10)
2.50.00.00.30.7(11)
0.03.31.60.00.0(12)
 ＊ADRB2 haplotypes were analyzed with 13 SNPs (see Drysdale et al. 2000 for details).
Table 4 Diferences in ADRB2 haplotype frequency among ethnic groups
IDENTIFICATION OF NOVEL SNPS
A 2973 base pair (bp) fragment of the ADRB2 pro-
moter, up to the coding region, was PCR amplified
from 24 non-asthmatic subjects using the following
primer pair: 5’-
AGATCTCTAGAGGTTCAAGAGATTCTCCTG-3’ and
5 ’ -AGATCAAGCT-TTGCCCTTCCTTCTGCATATC-
3’. PCR products were sequenced using dye termina-
tor chemistry (BigDyeTM, Applied Biosystems, Fos-
ter City, CA, USA) and the ABI PRISM 3700 DNA
Analyzer (Applied Biosystems, Foster, CA, USA). Se-
quencing primers were designed to provide overlap-
ping 500 bp sequences. The sequence data were as-
sembled with SequencherTM software (Gene Codes
Corporation, Ann Arbor, MI, USA) to identify novel
SNPs.
MOLECULAR-BASED HAPLOTYPE ANALYSIS
Two approaches were used to obtain unphased and
phased genotypes of the ADRB2 gene . Unphased
genotypes from both parental alleles were deter-
mined by directly sequencing polymerase-chain-
reaction (PCR) products amplified with the primers
described above. The PCR-RFLP method was used if
direct sequencing could not generate genotypes. The
PCR reactions for restriction-fragment-length-
polymorphisms (RFLP) were performed as follows:
initial denaturation at 94 for 2 minutes, followed by
35 cycles of amplification at 94 for 30 seconds, an-
nealing for 30 seconds and extension for 2 minutes.
Conditions of the PCR-RFLP analysis are shown in
Table 1. RFLP assays were designed with mis-
matched primers that generate restriction sites.18 Be-
tween 2 and 5 µl of the PCR products was digested
overnight with 13 units of enzyme per reaction in a
total volume of 10 µl, according to the manufacturers
instructions . Digested products were separated on
2.5  5% agarose gels ( Nakaraiteck BioProducts ,
Osaka, Japan) and visualized by staining with ethid-
ium bromide. Phased ADRB2 genotypes were deter-
mined by digesting PCR products with XbaI and
HindIII, and cloning into pBluescriptII vector
(Stratagene, La Jolla, CA, USA). After transformation
of Escherichia coli JM109 Electro-CellsTM (Takara Bio
Inc., Shiga, Japan), a single colony representing the
sequence from one chromosome was isolated and se-
quenced as described above. The difference between
the genomic and the cloned sequences provided the
phased genotypes for both chromosomes.
RESULTS
IDENTIFICATION OF A NOVEL SNP
We used PCR direct sequencing of genomic DNA
from 24 non-asthmatics to identify a novel SNP in the
promoter region ( −839 ) . This SNP conformed to
Hardy-Weinberg equilibrium (HWE) and had not
been deposited in the dbSNP database of the Na-
tional Center for Biotechnology Information (NCBI).
UNPHASED SNP ANALYSIS
To ascertain the haplotypes of ADRB2 in Japanese
populations , we first analyzed the unphased geno-
types of 46 asthmatic and 100 non-asthmatic subjects
using direct sequencing of PCR products and a PCR
restriction-fragment length polymorphism ( RFLP )
method. Table 2 shows the localization of SNPs and
identification of ADRB2 genotypes in the Japanese
population. SNPs at −709, −406, 100, 491 and 1,098
were found not to be polymorphic in the Japanese
population. Among the polymorphic SNPs, no signifi-
cant difference was observed in allele and genotype
frequencies between non-asthmatic and asthmatic
subjects.
MOLECULAR-BASED HAPLOTYPE STUDIES
ADRB2 haplotypes were determined by comparing
PCR-amplified sequences of 3 kb promoter region
with sequences of cloned fragments . Of the 2 20
Haplotype Analysis of ADRB2 in Japanese
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CaucasiansJapanese
Diplotypes
FrequencyFrequencyN
6.620.5304/6
－18.5276/6
11.616.4244/4
0.87.5111/4
30.66.2 92/4
18.26.2 92/6
0.84.1 61/6
－4.1 64/13
－2.7 410/18
－2.1 31/2
－2.1 36/13
－2.1 315/19
－0.7 11/1
－0.7 11/11
20.70.7 12/2
－0.7 14/19
－0.7 15/16
－0.7 15/19
－0.7 16/19
－0.7 16/20
－0.7 18/11
－0.7 114/16
－0.7 117/21
1.7－－2/5
0.8－－2/11
1.7－－4/10
0.8－－2/3
0.8－－2/7
0.8－－2/8
0.8－－3/4
0.8－－4/5
0.8－－4/7
0.8－－4/8
0.8－－6/7
Diplotypes were analyzed with 13 SNPs [see Drysdale et al. 
2000 for details]. N denotes the number of Japanese in each 
group.
Table 5 Diferences in ADRB2 diplotype frequencies be-
tween Japanese and Caucasians
( 1,048,576 ) possible combinations of these SNPs ,
only 42 haplotypes and 54 diplotypes were found to
exist in the Japanese population (Tables 3,5). To de-
termine whether there were any haplotypes associ-
ated with asthma, we performed a Chi square test be-
tween asthmatics and non-asthmatics. Haplotype dis-
tributions were not significantly different between
these two groups.
HAPLOTYPES AND DIPLOTYPES IN DIFFERENT
ETHNIC GROUPS
To compare the distribution of ADRB2 haplotypes
among different ethnic groups, we reorganized the
haplotypes using 13 SNPs that were analyzed by
Drysdale et al..5 We identified 17 haplotypes and 23
diplotypes in the Japanese population , whereas 12
haplotypes and 18 diplotypes were reported in Cauca-
sians. Furthermore, there were extreme differences
in allele frequencies between Japanese and Cauca-
sians (Table 4). Haplotype 2, which was the most fre-
quent in Caucasians (48.3%), was only present in 7.9%
of the Japanese population. By contrast, haplotype 6,
which was the most frequent in Japanese (35.6%) to-
gether with haplotype 4, was only present in 13.2% of
Caucasians. Diplotype 24, which was the most fre-
quent in Caucasians (30.6%), was seen in only 6.2% of
the Japanese population. By contrast, diplotype 66,
which was the most frequent in Japanese (18.5%), was
absent in Caucasians (Table 5). To address the ques-
tion of why haplotype frequencies were so different
between Japanese and Caucasians, linkage disequilib-
rium (LD) in Japanese was quantitated, as described
by Hill and Weir.19 Its pattern in the Japanese popula-
tion seemed to be similar to those of Caucasians, ex-
cept for the SNP at position −1,023. This SNP showed
strong LD to −468, −367, −47 and −20 in Caucasians,5
but showed only weak LD in Japanese (Fig. 1).
HARDY-WEINBERG EQUILIBRIUM AND NU-
CLEOTIDE DIVERSITY
All SNPs, except for +1239TG, and all haplotypes
were found to conform to HWE. Within ADRB2, the
observed frequencies at + 1239 TG in the non-
asthmatic sample group deviated from the expected
values (p = 0.021). However, when the test was per-
formed with Bonferroni’s correction to adjust for mul-
tiple comparisons, none of the allele frequencies in
the non-asthmatic group deviated from HWE.
DISCUSSION
Many chromosome loci have been reported to be as-
sociated with asthma and atopy, including 5q, 6p, 11q
12q and 17p.20,21 ADRB2, which is localized at 5q31
q32, has been extensively studied as a candidate gene
for asthma and atopy.22 Allele frequencies of ADRB2
polymorphisms have been reported to differ among
ethnic groups.23 In the present study, we examined
the frequencies of allele, genotypes, haplotypes and
diplotypes of ADRB2, which were analyzed in 100
non-asthmatic and 46 asthmatic Japanese subjects .
No significant differences were detected in the fre-
quencies of each SNP between asthmatic and non-
asthmatic groups (Chi square test). No association
was observed between ADRB 2 haplotypes and
asthma (Chi square test , p = 0.0940.227 ) , in 42
haplotypes constructed with 15 SNPs on 292 chromo-
somes (Table 3). Therefore, we combined both the
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Fig. 1 Linkage disequilibrium between ADRB2 SNPs. Genotypes from the Japanese 
samples were determined at the 15 loci shown in Table 3, and the degree of linkage dise-
quilibrium (r2) between SNPs was calculated using SNP Analyzer software (Dynacom Co., 
Ltd., Chiba, Japan). Results are color coded as folows: white, 0―0.5; half shaded, 0.5―
0.8; shaded, 0.8―1.0.
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r2
frequencies of asthmatic and non-asthmatic subjects
for haplotypes and diplotypes for a comparative eth-
nic study . ADRB2 allele frequencies and genotype
distributions in African Americans were similar to
those in Japanese . Evans et al .23 suggested that
ADRB2 codon 16 and 27 frequencies (SNP positions
46 and 79 in Tables 1,2) fall into two clusters of Cau-
casians and African-Chinese. Other investigations in-
cluded Japanese and Egyptians with the African-
Chinese cluster.24 The frequencies of Japanese in the
present study were similar to those of African-
Chinese previously reported . 23,24 In the present
study, the high frequencies of haplotypes 1, 2, 4 and 6
(Table 4) support the inclusion of Japanese in the
African-Chinese cluster, which was also observed to
have high frequencies of haplotypes 1, 2, 4 and 6
compared with Caucasians.23 It is of interest that ap-
proximately 70% of haplotypes were shared between
the Japanese and Caucasians, whereas only 30% of
the diplotypes were shared (Tables 4,5). From these
results it can be suggested that Caucasians have a
unique distribution of ADRB2 SNPs. In addition, a re-
cent relatively large prospective study has suggested
that adverse effects of regular inhalational therapy
with β2-agonist occur in Caucasian asthmatic subjects
with the ArgArg genotype at aminoacid residue 16.14
In contrast, our previous prospective study revealed
opposite results indicating that the GlyGly genotype
is related to adverse effects of β2-agonist regular use
in Japanese asthmatics.13 The results of the present
study revealed that, a major part of Caucasian sub-
jects with the Arg16 genotype (A allele in nucleotide
46) belong to haplotype 2 (48.3%) and 4 (33.0%). By
contrast, Japanese subjects with the same genotype
belong to haplotype 4 (36%) and 6 (35.6%). In this con-
text, more than half of the Japanese subjects with the
Arg16 genotype belong to the different haplotype
when compared to Caucasian.
We identified a new diplotype (66) , which oc-
curred most frequently in Japanese subjects (18.5%)
Haplotype Analysis of ADRB2 in Japanese
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and was not seen in Caucasians (Table 5). An associa-
tion study between the ADRB2 haplotype and β2-
stimulant response in Caucasian populations sug-
gested that patients sensitive to the β2-stimulant have
diplotype 46 rather than 44.5 It is therefore of inter-
est to assess any increased sensitivity to the β 2-
stimulants in patients with the 66 diplotype, which
might be useful for association studies between the
ADRB2 haplotype and bronchodilator responses to
the β2-stimulants.
From these results, we conclude that ADRB2 may
be involved in the pharmacogenetics of asthma ,
rather than contributing to the pathogenesis, in the
absence of an association between ADRB2 polymor-
phisms and asthma. Our data on ADRB2 haplotype
analysis in the Japanese population might be useful
for future pharmacogenomic studies on β2-stimulant
responsiveness, and provide a better understanding
of ethnic and individual differences in drug re-
sponses, which could contribute to the individualiza-
tion of drug therapy.
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